A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT05160480
Status
Enrolling By Invitation

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Total-body PET imaging — DIAGNOSTIC_TEST
    Total-body PET imaging at different timepoints

Study Details

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Key Dates

Start date
Jun 7, 2024
Status verified
Jan 2026
Primary completion
Sep 1, 2026
Completion
Sep 1, 2026

Study Design

Enrollment
9 participants (estimated)

Arms

  • Arm: Total-body PET scan
    All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.

Primary Outcome Measure

measure radiotracer avidity [ Time Frame: One study imaging visit lasting up to 10 hours ]

Locations (1)

FacilityCityStateZIPSite coordinators
UC Davis EXPLORER Molecular Imaging CenterSacramentoCalifornia95816-

Find similar trials in Sacramento, CA

By condition
Breast cancerNeuroendocrine tumorsProstate cancer
By specialty
OncologyBreast oncologyWomen's healthProstate oncologyMen's healthUrology
By research site
UC Davis EXPLORER Molecular Imaging Center· Sacramento, CA

Related Studies